EGFR and non-small cell lung carcinoma: Afatinib is an irreversible pan-HER tyrosine kinase inhibitor (TKI) targeting EGFR, HER2, and HER4, currently approved for the treatment of adult patients with advanced NSCLC with activating EGFR mutation(s) or for platinum-resistant squamous NSLC.